CERT earnings

RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quarter Highlights: Appointment of Jon Resnick as Chief Executive Officer and Member of the Board of Directors, effective January 1st, 2026.Revenue was $103.6 million, compared to $100.4 million i

RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic

RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%. Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing

RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulation softw

RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compared to $55.1 million in the second quarter of 2024, representing growth of 5%. Net loss was $2.0 million, compared to a net loss of $12.6 million in the second quarter of 2024, repr

RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using b

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock. "We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services," said

RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%. Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 millio

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using

RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024. Second Quarter Highlights: Revenue was $93.3 million, compared to $90.5 million in the second quarter of 2023, representing growth of 3%. Software revenue was $38.2 million, compared to $33.7 million in the second quarter of 2023, representing growth of 13%.Services revenue was $55.1 million, compared to $56.7 million in the second quarter of 2023, representing a decline of 3%. Net loss was $12.6 million, compared to a net income of $4.7 million in the second quarter of 2023.Adjuste

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using bio

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: Revenue was $96.7 million, compared to $90.3 million in the first quarter of 2023, representing growth of 7%.  Software revenue was $39.3 million, compared to $33.0 million in the first quarter of 2023, representing growth of 19%.Services revenue was $57.3 million, flat compared to $57.3 million in the first quarter of 2023. Net loss was $4.7 million, compared to a net income of $1.4 million in the first quarter of 2023.Adjusted EBITDA was $29.1 million, compared to $32.3

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that Company management will participate at the upcoming BofA Securities Healthcare Conference. Company management will present at 3:40PM PT on Tuesday, May 14th. Live and archived w

PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: Revenue was $88.0 million, compared to $86.6 million in the fourth quarter of 2022, representing growth of 2% over the fourth quarter of 2022.Strong sequential growth with record software bookings and broad-based recovery in technology enabled services bookings during the quarter.Net loss was $12.5 million, compared to a net income of $9.2 million in the fourth quarter of 2022. Net loss includes a $12.8 million increase in fair value of the remeasurement of conting

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that Company management will participate at the upcoming Barclays 26th Annual Global Healthcare Conference. Company management will present at 1:05PM ET on Wednes

PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: Revenue was $85.6 million, compared to $84.7 million in the third quarter of 2022, representing growth of 1% over the third quarter of 2022. Broad based recovery in services bookings during the quarter. Net loss was $49.0 million, compared to a net income of $3.9 million in the third quarter of 2022. Net loss includes a $47.0 million goodwill impairment expense in the third quarter of 2023 related to the Regulatory business. Adjusted EBITDA was $28.8 million, compared

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that Company management will participate in the upcoming Stephens Annual Investment Conference. Company management will present at 2:00PM CT on Wednesday, November 15th. Live and

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: Revenue was $90.5 million, compared to $82.8 million in the second quarter of 2022, representing growth of 9% over the second quarter of 2022 on a reported basis and 10% at constant currency.Net income was $4.7 million, compared to a net loss of $0.6 million in the second quarter of 2022.Adjusted EBITDA was $32.4 million, compared to $28.0 million in the second quarter of 2022. "During the second quarter our software business performed well, but we experienced lower gr

PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using proprietary bio

PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. First Quarter Highlights: Revenue was $90.3 million, compared to $81.6 million in the first quarter of 2022, representing growth of 11% over the first quarter of 2022 on a reported basis and 13% at constant currency.Net income was $1.4 million, compared to $2.2 million in the first quarter of 2022, representing a decrease of 39% over the first quarter of 2022.Adjusted EBITDA was $32.3 million, compared to $27.7million in the first quarter of 2022, representing growth of 17% over the first quarter o

PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that Company management will participate at the upcoming BofA Securities 2023 Healthcare Conference. Company management will present at 8:40AM PT on Wednesday, May 10th. Live and arch

PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using pr

PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using proprietary biosi

PRINCETON, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights: Revenue was $82.8 million, compared to $70.1 million in the second quarter of 2021, representing growth of 18% over the second quarter of 2021 on a reported basis and 21% at constant currency.Excluding Pinnacle 21, revenue was $75.8 million, representing growth of 8% over the second quarter of 2021 on a reported basis and 11% at constant currency.Net loss was $0.6 million, compared to net loss of $2.9 million in the second quarter

PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using proprietary biosi

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million, compared to $66.7 million in the first quarter of 2021, representing growth of 22% over the first quarter of 2021. Excluding Pinnacle 21, revenue was $75.6 million, representing growth of 13% over the first quarter of 2021.  Net income was $2.2 million, compared to net income of $1.1 million in the first quarter of 2021, representing growth of 110% over the first quarter of 2021.Adjusted EBITDA was $27.7 million, compared to $23.9 million in the

PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 1290087. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara

PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 4688502. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About

PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 1968232. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCert

PRINCETON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2021. Highlights: Revenue was $70.1 million, representing growth of 15% over the second quarter of 2020Net loss was ($2.9) million, compared to a net income of $2.8 million in the second quarter of 2020Adjusted EBITDA was $25.5 million, representing growth of 1% over the second quarter of 2020Announced agreement to acquire Pinnacle 21, a leader in data standardization software for pharmaceutical clinical data, for $310 million in cash and stock, with a closing expected in early Q4 of 2021Raised 2021 gu

PRINCETON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced it has signed a definitive agreement to acquire Pinnacle 21 for $310 million in cash and stock. Pinnacle 21's software tools are used to validate compliance to the Clinical Data Interchange Standards Consortium (CDISC) standards, which is required by the US Food & Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for drug submissions and preferred by China's National Medical Products Administration (NMPA). "We are excited to welcome Pinnacle 21 to Certara as we execute on our strategy to invest in innovation to increase the